Survival, Years of Life Lost and Attrition Rates in Multiple Myeloma Patients in France.

IF 2.7 4区医学 Q2 HEMATOLOGY

Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2025-03-04 DOI:10.1016/j.clml.2025.03.004

Aurore Perrot, Fanny Raguideau, Helene Denis, Martin Prodel, Matthieu Javelot, Marie Pierres, Cyrille Touzeau

{"title":"Survival, Years of Life Lost and Attrition Rates in Multiple Myeloma Patients in France.","authors":"Aurore Perrot, Fanny Raguideau, Helene Denis, Martin Prodel, Matthieu Javelot, Marie Pierres, Cyrille Touzeau","doi":"10.1016/j.clml.2025.03.004","DOIUrl":null,"url":null,"abstract":"Background: In a context of strong evolution of multiple myeloma (MM) treatment paradigm, real-world data allow a better understandingthe patients' medical needs.Methods: The present analyses from the MYLORD study were designed to provide recent data on MM patients: characteristics, overall survival (OS), years of life lost (YLL) and attrition rates, using the French National Health Insurance Database (SNDS). It is based on a cohort of 33,032 MM patients who initiated a frontline therapy from 2014 to 2021 in France and who were followed until 2021.Results: The 5-year OS rate is estimated at 51.9% (95% CI: 51.2-52.6). This rate is 78.3% (95% CI: 77.1-79.5) for patients with frontline autologous stem cell transplant (L1T) and 43.6% (95% CI: 42.8-44.4) for those without transplant (L1NT). The excess of mortality in MM patients is revealed by 12.3 YLL versus the matched general population and is higher in L1T patients than those L1NT (17 vs. 11 years). The attrition rate is important in MM patients with 38% of patients who did not benefit from at least 2 lines of treatment and is higher in L1NT patients than those in L1T (41% vs. 29%). Also, the majority of L1NT patients did not receive a L2 because of death, whereas it is because of stay in line status for L1T patients.Conclusion: These results emphasize the urgency to treat MM patients with the best and tailored treatment strategy available, for all MM patients beneficiating or not from a transplant in frontline therapy. Further studies will be needed to assess the impact of new therapeutic options in real life.","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma, Myeloma & Leukemia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clml.2025.03.004","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: In a context of strong evolution of multiple myeloma (MM) treatment paradigm, real-world data allow a better understandingthe patients' medical needs.

Methods: The present analyses from the MYLORD study were designed to provide recent data on MM patients: characteristics, overall survival (OS), years of life lost (YLL) and attrition rates, using the French National Health Insurance Database (SNDS). It is based on a cohort of 33,032 MM patients who initiated a frontline therapy from 2014 to 2021 in France and who were followed until 2021.

Results: The 5-year OS rate is estimated at 51.9% (95% CI: 51.2-52.6). This rate is 78.3% (95% CI: 77.1-79.5) for patients with frontline autologous stem cell transplant (L1T) and 43.6% (95% CI: 42.8-44.4) for those without transplant (L1NT). The excess of mortality in MM patients is revealed by 12.3 YLL versus the matched general population and is higher in L1T patients than those L1NT (17 vs. 11 years). The attrition rate is important in MM patients with 38% of patients who did not benefit from at least 2 lines of treatment and is higher in L1NT patients than those in L1T (41% vs. 29%). Also, the majority of L1NT patients did not receive a L2 because of death, whereas it is because of stay in line status for L1T patients.

Conclusion: These results emphasize the urgency to treat MM patients with the best and tailored treatment strategy available, for all MM patients beneficiating or not from a transplant in frontline therapy. Further studies will be needed to assess the impact of new therapeutic options in real life.

查看原文本刊更多论文

法国多发性骨髓瘤患者的存活率、寿命损失年数和自然减退率。

背景：在多发性骨髓瘤（MM）治疗模式不断发展的背景下，真实世界的数据可以更好地了解患者的医疗需求。方法：目前来自MYLORD研究的分析旨在提供MM患者的最新数据：特征，总生存期（OS），生命损失年数（YLL）和损耗率，使用法国国家健康保险数据库（SNDS）。该研究基于2014年至2021年在法国开始一线治疗的33032名MM患者的队列，并随访至2021年。结果：5年OS率估计为51.9% （95% CI: 51.2-52.6）。一线自体干细胞移植（L1T）患者的这一比例为78.3% (95% CI: 77.1-79.5)，未移植（L1NT）患者的这一比例为43.6% （95% CI: 42.8-44.4）。MM患者的死亡率高于匹配的普通人群（12.3年），L1T患者的死亡率高于L1NT患者（17年vs 11年）。磨耗率在MM患者中很重要，38%的患者没有从至少2线治疗中获益，L1NT患者的磨耗率高于L1T患者（41%对29%）。此外，大多数L1NT患者没有因为死亡而接受L2，而这是因为L1NT患者处于排队状态。结论：这些结果强调了采用最佳和量身定制的治疗策略治疗MM患者的紧迫性，所有MM患者在一线治疗中接受移植或不接受移植。需要进一步的研究来评估新的治疗选择在现实生活中的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.